MedTrace Logo

Benfotiamine in Diabetic Nephropathy

NCT00565318 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2009-11-16

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of benfotiamine supplementation in patients with diabetic nephropathy, and to determine whether it will slow down the progression to end-stage renal disease (ESRD).

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Benfotiamine

3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.

DRUG

Placebo

3x 1 film coated tablet daily. Duration: 12 weeks.

Sponsors & Collaborators

  • Isala

    collaborator OTHER

  • Wörwag Pharma GmbH & Co. KG

    collaborator UNKNOWN

  • Predictions Network

    collaborator UNKNOWN

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • G J Navis, MD, PhD · University Medical Center Groningen

  • H JG Bilo, MD, PhD · Isala

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565318 on ClinicalTrials.gov